MarketBeat Instant News Alerts MarketBeat Instant News Alerts - Page 692 August 20, 2026 6:06 AM ETCantor Fitzgerald Boosts Okta (NASDAQ:OKTA) Price Target to $170.00MarketBeatNASDAQ:OKTARead Cantor Fitzgerald Boosts Okta (NASDAQ:OKTA) Price Target to $170.00August 20, 2026 6:06 AM ETMilestone Pharmaceuticals (NASDAQ:MIST) Coverage Initiated at Cantor FitzgeraldMarketBeatNASDAQ:MISTRead Milestone Pharmaceuticals (NASDAQ:MIST) Coverage Initiated at Cantor FitzgeraldAugust 20, 2026 6:06 AM ETNeedham & Company LLC Forecasts Strong Price Appreciation for NIQ Global Intelligence (NYSE:NIQ) StockMarketBeatNYSE:NIQRead Needham & Company LLC Forecasts Strong Price Appreciation for NIQ Global Intelligence (NYSE:NIQ) StockAugust 20, 2026 6:06 AM ETFigure Technology Solutions (NASDAQ:FIGR) Given "Buy" Rating at Needham & Company LLCMarketBeatNASDAQ:FIGRRead Figure Technology Solutions (NASDAQ:FIGR) Given "Buy" Rating at Needham & Company LLCAugust 20, 2026 6:06 AM ETMorgan Stanley Forecasts Strong Price Appreciation for Moderna (NASDAQ:MRNA) StockMarketBeatNASDAQ:MRNARead Morgan Stanley Forecasts Strong Price Appreciation for Moderna (NASDAQ:MRNA) StockAugust 20, 2026 6:06 AM ETZevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC WainwrightMarketBeatNASDAQ:ZVRARead Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC WainwrightAugust 20, 2026 6:06 AM ETBTIG Research Issues Positive Forecast for OrthoPediatrics (NASDAQ:KIDS) Stock PriceMarketBeatNASDAQ:KIDSRead BTIG Research Issues Positive Forecast for OrthoPediatrics (NASDAQ:KIDS) Stock PriceAugust 20, 2026 6:06 AM ETLENSAR (NASDAQ:LNSR) Price Target Raised to $10.00MarketBeatNASDAQ:LNSRRead LENSAR (NASDAQ:LNSR) Price Target Raised to $10.00August 20, 2026 6:06 AM ETBTIG Research Boosts Glaukos (NYSE:GKOS) Price Target to $202.00MarketBeatNYSE:GKOSRead BTIG Research Boosts Glaukos (NYSE:GKOS) Price Target to $202.00August 20, 2026 6:06 AM ETSeaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC WainwrightMarketBeatNASDAQ:SPTXRead Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC WainwrightAugust 20, 2026 6:06 AM ETMerck & Co., Inc. (NYSE:MRK) Raised to Overweight at Morgan StanleyMarketBeatNYSE:MRKRead Merck & Co., Inc. (NYSE:MRK) Raised to Overweight at Morgan StanleyAugust 20, 2026 6:06 AM ETNeedham & Company LLC Forecasts Strong Price Appreciation for Analog Devices (NASDAQ:ADI) StockMarketBeatNASDAQ:ADIRead Needham & Company LLC Forecasts Strong Price Appreciation for Analog Devices (NASDAQ:ADI) StockAugust 20, 2026 6:06 AM ETAscendiant Capital Markets Issues Pessimistic Forecast for Travelzoo (NASDAQ:TZOO) Stock PriceMarketBeatNASDAQ:TZOORead Ascendiant Capital Markets Issues Pessimistic Forecast for Travelzoo (NASDAQ:TZOO) Stock PriceAugust 20, 2026 6:06 AM ETAscendiant Capital Markets Cuts Cingulate (NASDAQ:CING) Price Target to $44.00MarketBeatNASDAQ:CINGRead Ascendiant Capital Markets Cuts Cingulate (NASDAQ:CING) Price Target to $44.00August 20, 2026 6:06 AM ETBTIG Research Reiterates "Buy" Rating for BILL (NYSE:BILL)MarketBeatNYSE:BILLRead BTIG Research Reiterates "Buy" Rating for BILL (NYSE:BILL)August 20, 2026 6:06 AM ETCantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) StockMarketBeatNASDAQ:RARERead Cantor Fitzgerald Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) StockAugust 20, 2026 6:06 AM ETKeefe, Bruyette & Woods Reiterates "Underperform" Rating for Allstate (NYSE:ALL)MarketBeatNYSE:ALLRead Keefe, Bruyette & Woods Reiterates "Underperform" Rating for Allstate (NYSE:ALL)August 20, 2026 6:06 AM ETProgressive (NYSE:PGR) Upgraded at Keefe, Bruyette & WoodsMarketBeatNYSE:PGRRead Progressive (NYSE:PGR) Upgraded at Keefe, Bruyette & WoodsAugust 20, 2026 6:06 AM ETIncyte (NASDAQ:INCY) Earns Buy Rating from Analysts at Canaccord Genuity GroupMarketBeatNASDAQ:INCYRead Incyte (NASDAQ:INCY) Earns Buy Rating from Analysts at Canaccord Genuity GroupAugust 20, 2026 6:06 AM ETProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Analysts at Bank of AmericaMarketBeatNASDAQ:PRQRRead ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Analysts at Bank of America Featured Articles and OffersThe AI Boom Is Turning This Cable Maker Into a Stock to WatchBy Peter Frank | August 18, 2026The end may be near for these iconic stocksFrom Chaikin Analytics (Ad)5 Reasons the S&P 500 Could Keep Rallying Through Year-EndBy Thomas Hughes | August 20, 2026Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It MattersBy Jeffrey Neal Johnson | August 24, 2026Bloom Energy’s AI Surge Meets a Valuation Reality CheckBy Peter Frank | August 19, 2026Silicon Valley Insider: "Forget AI Stocks"From Brownstone Research (Ad)Tesla's Cybercab Launch Could Reshape Margins for Uber and LyftBy Jeffrey Neal Johnson | August 19, 2026VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?By Jessica Mitacek | August 23, 2026 Alert CategoriesAll AlertsAnalystCongressional TradesConsensusCorporate BuybackCorporate Event TranscriptStock ListDividendEarningsEarnings PreviewEarnings Transcript HighlightsEstimatesGuidanceInsider TradeLockup ExpirationMarketBeat List ArticlesOptionsPriceSEC FilingStock Split Page 692 of 692 « Most Recent‹ More Recent686687688689690691692 Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
